Sensei Biotherapeutics Files 8-K: Material Agreements & Security Holder Rights
Ticker: SNSE · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, security-holder-rights, filing
TL;DR
Sensei Biotherapeutics filed an 8-K detailing material agreements and changes to security holder rights.
AI Summary
On March 5, 2024, Sensei Biotherapeutics, Inc. entered into a material definitive agreement. The company also made modifications to the rights of its security holders and filed financial statements and exhibits as part of this 8-K filing.
Why It Matters
This filing indicates significant corporate actions, including new agreements and changes affecting security holders, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce new risks or alter existing ones for investors.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement did Sensei Biotherapeutics enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 5, 2024.
What were the modifications to the rights of security holders?
The filing indicates modifications were made to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
What financial statements and exhibits were filed?
The filing states that financial statements and exhibits were filed, but their content is not described in the provided text.
What is Sensei Biotherapeutics' principal executive office address?
Sensei Biotherapeutics, Inc.'s principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 779 words · 3 min read · ~3 pages · Grade level 10 · Accepted 2024-03-05 16:44:11
Filing Documents
- d792997d8k.htm (8-K) — 30KB
- d792997dex43.htm (EX-4.3) — 20KB
- 0001193125-24-059356.txt ( ) — 215KB
- snse-20240305.xsd (EX-101.SCH) — 4KB
- snse-20240305_def.xml (EX-101.DEF) — 14KB
- snse-20240305_lab.xml (EX-101.LAB) — 23KB
- snse-20240305_pre.xml (EX-101.PRE) — 15KB
- d792997d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 4.1 Stockholder Rights Agreement, dated as of March 7, 2023, by and between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (which includes the form of Right Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form 8-A, filled with the Securities and Exchange Commission on March 7, 2023, File No. 001-39980). 4.2 Amendment to Stockholder Rights Agreement, dated as of June 23, 2023, by and between Sensei Biotherapeutics, Inc. and American Stock Transfer & Trust Company, LLC, as rights agent (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 23, 2023, File No. 001-39980). 4.3 Second Amendment to Stockholder Rights Agreement, dated as of March 5, 2024, by and between Sensei Biotherapeutics, Inc. and Equiniti Trust Company, LLC, as rights agent. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date March 5, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3